Qualyst, Inc. today announced that it has accomplished the closing of its Series B Preferred Stock Offering, bringing total funds raised through the Series A and Series B financing rounds to $5.5 million. Specific financial details relating to Series B were not disclosed. Burton Advisers Ltd. (of London) acted as the exclusive advisor and financial arranger for the Offering.
American Venture Magazine
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
India to Regulate Gowns, Drapes as Devices
The Medical Technology Association of India says will work with its member companies to streamline the transition.
Solicitor General OK’d to Argue for Merck in Fosamax Case
The case addresses when an FDA decision to reject proposed labeling changes of a brand drug pre-empts failure-to-warn laws.
FDAnews Drug Daily Bulletin
QUALYST CLOSES SERIES B VENTURE CAPITAL FINANCING
May 5, 2006
